With regard to the choice of bone-protecting agent, denosumab (Xgeva) improved bone density and reduced fracture risk in a placebo-controlled trial involving men with non-metastatic HSPC. Denosumab ...

The "try and fail" language is flawed when weight loss is used as the primary measure of success with lifestyle interventions ...